Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Eisai
Eisai
Clarivate Drugs to Watch Report Highlights Four Likely Blockbusters Among Drugs Launching in 2021
PR Newswire
Tue, 03/9/21 - 10:45 am
Clarivate
Biogen
Eisai
aducanumab
UCB Pharma
bimekizumab
Relugolix
Pfizer
Takeda
Myovant
vericiguat
Bayer
Merck
Merck's Keytruda Plus Eisai's Lenvima Could Open New Standard of Care in Renal Cancer
BioSpace
Tue, 02/16/21 - 11:12 am
Merck
ASCO GU
Keytruda
Eisai
Lenvima
renal cell carcinoma
FDA extends review period for Biogen's Alzheimer's drug
Reuters
Fri, 01/29/21 - 10:06 am
Biogen
Eisai
FDA
aducanumab
Alzheimer's disease
Aducanumab tops 2021’s biggest potential launches
EP Vantage
Mon, 01/18/21 - 01:04 pm
drug launches
Biogen
Eisai
aducanumab
efgartigimod
Argenx
Evrenzo
FibroGen
Astellas
AstraZeneca
Leqvio
Novartis
UCB Pharma
bimekizumab
Ascendis Pharma
Bluebird Bio
Bristol-Myers Squibb
ide-cel
liso-cel
AXS-05
Axsome Therapeutics
voclosporin
Aurinia
Could Keytruda/Lenvima Combo Help Treat Advanced Renal Cell Carcinoma?
BioSpace
Tue, 11/10/20 - 11:10 am
Merck
Eisai
Keytruda
Lenvima
clinical trials
advanced renal cell carcinoma
ESMO: Where will Merck, Eisai take Keytruda-Lenvima next? Ovarian and colorectal cancer could be good options, data show
Fierce Pharma
Sun, 09/20/20 - 07:44 pm
Merck
Eisai
Keytruda
Lenvima
ovarian cancer
colorectal cancer
Eisai is creating a new US corporate, R&D HQ in Roche’s old Nutley, NJ campus
Endpoints
Tue, 08/11/20 - 12:31 pm
Eisai
Roche
R&D
New Jersey
Biogen nabs speedy FDA review for controversial Alzheimer’s drug
Fierce Biotech
Fri, 08/7/20 - 11:00 am
Biogen
aducanumab
Eisai
FDA
Alzheimer's disease
priority review
Biogen and Eisai trial drug in asymptomatic Alzheimer’s disease
Pharmaforum
Tue, 07/14/20 - 10:31 am
Biogen
Eisai
Alzheimer's disease
amyloid
BAN2401
clinical trials
Chasing Merck, Eisai launches insomnia drug Dayvigo in Japan
Pharmaforum
Tue, 07/7/20 - 10:40 am
Eisai
Dayvigo
Japan
insomnia
Merck
Belsomra
ASCO: Merck, Eisai pad case for liver cancer nod with Keytruda-Lenvima combo data
Fierce Pharma
Mon, 06/1/20 - 12:00 am
Merck
Eisai
liver cancer
ASCO 2020
Keytrua
Lenvima
clinical trials
Pharma giants including Novartis collaborate on COVID-19 therapies
Pharmaforum
Thu, 03/26/20 - 10:38 am
JNJ
Novartis
Boehringer Ingelheim
Biomerieux
Eisai
Eli Lilly
Gilead Sciences
GSK
Merck
Merck KGaA
Pfizer
Sanofi
R&D
COVID-19
diagnostics
vaccines
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
Xconomy
Thu, 02/13/20 - 11:39 pm
Eisai
lorcaserin
Belviq
cancer
FDA
weight loss
Epizyme drug granted approval by FDA for rare cancer
BioPharma Dive
Thu, 01/23/20 - 11:52 pm
Epizyme
FDA
Tazverik
Eisai
epithelioid sarcoma
FDA Warns of Potential Cancer Risk With Weight Loss Drug
RAPS.org
Tue, 01/14/20 - 09:50 pm
FDA
Belviq
Eisai
cancer
FDA clears Eisai’s insomnia drug Dayvigo
Pharmaforum
Mon, 12/30/19 - 11:01 am
FDA
Eisai
Dayvigo
insomnia
Merck
Belsomra
Gilead gets ball rolling on JAKs game in Japan
Endpoints
Mon, 12/30/19 - 10:39 am
Gilead Sciences
Japan
filgotinib
Eisai
rheumatoid arthritis
Eisai preps for launch with insomnia med Dayvigo after buying out Purdue
Fierce Pharma
Mon, 12/23/19 - 11:36 pm
Eisai
Purdue
FDA
drug launches
insomnia
Dayvigo
Dova Pharma's bet on Eisai castoff spells gold as Sobi spends millions to acquire it
Endpoints
Mon, 09/30/19 - 12:06 pm
Dova Pharmaceuticals
Eisai
Swedish Orphan Biovitrum
M&A
ESMO: Merck, Eisai detail Keytruda-Lenvima combo results after triple endometrial cancer OK
Fierce Pharma
Sun, 09/29/19 - 09:37 pm
Merck
Eisai
Keytruda
Lenvima
endometrial cancer
ESMO
Pages
« first
‹ previous
…
3
4
5
6
7
8
9
10
11
…
next ›
last »